GLP-1 Receptor Agonist Market

The GLP-1 receptor agonist market consists of therapeutic agents that improve the body's insulin response while suppressing appetite, primarily serving patients with type 2 diabetes and obesity. The market's growth is driven by a rising preference for dual-purpose treatments that address both conditions simultaneously. Key growth factors also include increasing global rates of metabolic disorders and significant advancements in drug delivery technologies, such as oral tablets and auto-injectors, which enhance patient convenience.